The Influence of Hepatic and Renal Impairment on the Pharmacokinetics of a Treatment for Herpes Zoster, Amenamevir (ASP2151): Phase 1, Open-Label, Single-Dose, Parallel-Group Studies

The Influence of Hepatic and Renal Impairment on the Pharmacokinetics of a Treatment for Herpes... Adv Ther (2017) 34:2612–2624 DOI 10.1007/s12325-017-0643-3 ORIGINAL RESEARCH The Influence of Hepatic and Renal Impairment on the Pharmacokinetics of a Treatment for Herpes Zoster, Amenamevir (ASP2151): Phase 1, Open-Label, Single-Dose, Parallel-Group Studies . . . Tomohiro Kusawake Donna Kowalski Akitsugu Takada . . . . Kota Kato Masataka Katashima James J. Keirns Michaelene Lewand . . Kenneth C. Lasseter Thomas C. Marbury Richard A. Preston Received: September 25, 2017 / Published online: November 13, 2017 The Author(s) 2017. This article is an open access publication hepatic impairment and mild, moderate, and ABSTRACT severe renal impairment. Results: In the hepatic impairment study, the Introduction: Amenamevir (ASP2151) is a pharmacokinetic profile of amenamevir in par- nonnucleoside human herpesvirus helicase-pri- ticipants with moderate hepatic impairment mase inhibitor that was approved in Japan for was generally similar to that of participants the treatment of herpes zoster (shingles) in with normal hepatic function. In the renal 2017. This article reports the results of two impairment study, the area under the ame- clinical trials that investigated the effects of namevir concentration versus time curve from renal and hepatic impairment on the pharma- the time of dosing up to the time of the last cokinetics of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Advances in Therapy Springer Journals

The Influence of Hepatic and Renal Impairment on the Pharmacokinetics of a Treatment for Herpes Zoster, Amenamevir (ASP2151): Phase 1, Open-Label, Single-Dose, Parallel-Group Studies

Loading next page...
 
/lp/springer_journal/the-influence-of-hepatic-and-renal-impairment-on-the-pharmacokinetics-YZpRLkes1i
Publisher
Springer Healthcare
Copyright
Copyright © 2017 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine; Oncology; Cardiology; Rheumatology; Endocrinology; Pharmacology/Toxicology
ISSN
0741-238X
eISSN
1865-8652
D.O.I.
10.1007/s12325-017-0643-3
Publisher site
See Article on Publisher Site

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial